title: Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy.
abstract: Pirfenidone (PFD) is a new compound that prevents and even reverses the extracellular matrix accumulation in several organs as shown by experimental and clinical studies. In the present study, we examined the effect of PFD (500 mg/kg daily in the food) on the progression of chronic renal failure (CRF) in the 5/6 nephrectomy rat model. Proteinuria progressively increased in rats with renal ablation (C) at 12 weeks. Urinary protein excretion in PFD-treated rats (P) was numerically lower than C, but the difference did not reach statistical significance. In contrast, in the chronic phase, PFD improved renal function and reduced collagen accumulation detected by hydroxyproline content (OH-Pro) in the cortex of the remnant kidney. Although creatinine clearance decreased with time in C, the values in P were significantly better at 10 and 12 weeks. The OH-Pro in C at 12 weeks was significantly higher than that of no-ablation, sham-operated rats, whereas OH-Pro in CRF was lower in (P). Expression of mRNA for type IV and I collagen in the cortex also increased in C, but it was inhibited in (P). To study the role that TGF-beta plays in the regulatory process following CRF, we examined the expression of TGF-beta mRNA in this model. Levels of cortical TGF-beta mRNA in C were significantly elevated at 12 weeks. The increase was suppressed by PFD. These results demonstrate that PFD attenuates the development of CRF by preventing collagen accumulation in this model, and suggest that PFD can be clinically useful for treating CRF.
authors.affiliation: First Department of Internal Medicine, University of Tokyo School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shimizu
authors.forename: M
authors.initials: M
authors.lastname: Fukagawa
authors.forename: T
authors.initials: T
authors.lastname: Kuroda
authors.forename: S
authors.initials: S
authors.lastname: Hata
authors.forename: Y
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: M
authors.initials: M
authors.lastname: Nemoto
authors.forename: K
authors.initials: K
authors.lastname: Shirai
authors.forename: S
authors.initials: S
authors.lastname: Yamauchi
authors.forename: S B
authors.initials: SB
authors.lastname: Margolin
authors.forename: F
authors.initials: F
authors.lastname: Shimizu
authors.forename: K
authors.initials: K
authors.lastname: Kurokawa
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D015152:Blotting, Northern; D001835:Body Weight / Q000187:drug effects; D003094:Collagen / Q000378:metabolism*; D003404:Creatinine / Q000097:blood / Q000652:urine; D005355:Fibrosis / Q000139:chemically induced; D006909:Hydroxyproline / Q000097:blood / Q000652:urine; D007668:Kidney / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009392:Nephrectomy; D011728:Pyridones / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D016212:Transforming Growth Factor beta / Q000096:biosynthesis
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011728:Pyridones; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D003094:Collagen; D003404:Creatinine; C093844:pirfenidone; D006909:Hydroxyproline